Filing Flows › 4D Molecular Therapeutics (FDMT) › Q4 2024
4D Molecular Therapeutics (FDMT) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Feb 28, 2025
4D Molecular Therapeutics (FDMT) reported revenue of $1K for the fourth quarter 2024 (Q4 2024) and -67% from the quarter before.
4D Molecular Therapeutics, Q4 2024: revenue $1K, net loss $49.7M, operating cash flow −$45.9M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1K | -67% | — |
| Operating profit | −$56.1M | — | — |
| Net earnings | −$49.7M | — | — |
| Operating cash flow | −$45.9M | — | — |
What changed
Revenue was $1K in Q4 2024, down 67% from the previous quarter.
Operating costs exceeded revenue by $56.1M, an operating margin of -5611700.0%. The quarter ended with a net loss of $49.7M, wider than the previous quarter's $43.8M loss.
Operating cash flow was −$45.9M. Non-cash charges added back $1.1M of depreciation and amortization and $7.6M of share-based compensation. Working capital and other items used $4.9M. Capital expenditures of $949K exceeded it, leaving free cash flow of −$46.8M.
Questions
What was 4D Molecular Therapeutics' revenue in the fourth quarter 2024?
4D Molecular Therapeutics (FDMT) reported revenue of $1K for the fourth quarter 2024 (Q4 2024) and -67% from the quarter before.